BioMarin Swings to Q3 Loss on Soaring R&D, Revenue Up 3.7%

Ticker: BMRN · Form: 10-Q · Filed: Oct 28, 2025 · CIK: 1048477

Biomarin Pharmaceutical INC 10-Q Filing Summary
FieldDetail
CompanyBiomarin Pharmaceutical INC (BMRN)
Form Type10-Q
Filed DateOct 28, 2025
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$0.001 B, $0
Sentimentmixed

Sentiment: mixed

Topics: Biotechnology, Rare Disease, R&D Spending, Net Loss, Revenue Growth, Pharmaceuticals, Clinical Pipeline

Related Tickers: BMRN

TL;DR

**BioMarin's Q3 loss is a bitter pill, but the massive R&D spend could be a long-term growth shot if their pipeline delivers.**

AI Summary

BioMarin Pharmaceutical Inc. reported a net loss of $30.744 million for the three months ended September 30, 2025, a significant decline from a net income of $106.080 million in the same period of 2024. This was primarily driven by a substantial increase in research and development (R&D) expenses, which surged to $409.478 million in Q3 2025 from $184.901 million in Q3 2024, representing a 121.4% increase. Despite the quarterly loss, net product revenues increased by 3.7% to $760.812 million for the three months ended September 30, 2025, up from $733.867 million in the prior year. For the nine months ended September 30, 2025, the company achieved a net income of $395.474 million, an increase from $301.916 million in the same period of 2024, with total revenues growing to $2.346 billion from $2.106 billion. Key business changes include a significant acquisition, net of cash acquired, totaling $285.193 million during the nine months ended September 30, 2025, and acquired in-process research & development expense of $220.963 million. Risks highlighted include the ability to manage growth, successfully develop new products, and navigate extensive ongoing regulatory requirements from the FDA, EC, and EMA. The strategic outlook emphasizes continued innovation in genetically defined conditions, supported by eight commercial therapies and a strong pipeline.

Why It Matters

BioMarin's substantial increase in R&D spending, leading to a quarterly loss, signals aggressive investment in its pipeline, which could be a long-term positive for investors if successful new therapies emerge. However, the immediate net loss of $30.744 million for Q3 2025, compared to a profit in the prior year, might concern short-term investors and could impact stock performance. For employees, this R&D focus suggests job stability and growth opportunities in drug development. Customers and the broader market stand to benefit from potential new treatments for rare genetic conditions, intensifying competition in the specialized biotechnology sector.

Risk Assessment

Risk Level: high — The risk level is high due to the significant increase in R&D expenses, which jumped by 121.4% to $409.478 million in Q3 2025, leading to a net loss of $30.744 million. This aggressive spending, coupled with an acquisition of $285.193 million and acquired in-process R&D expense of $220.963 million, indicates substantial investment in unproven future products, carrying inherent development and regulatory risks as detailed in the 'Risk Factors Summary' regarding obtaining regulatory approval and successful commercialization.

Analyst Insight

Investors should closely monitor BioMarin's upcoming clinical trial results and regulatory milestones for its pipeline candidates, given the substantial R&D investment. Evaluate the long-term potential of their drug candidates against the immediate financial impact of increased expenses and the Q3 net loss. Consider this a growth-oriented play with higher risk.

Financial Highlights

debt To Equity
0.21
revenue
$2.346B
operating Margin
19.5%
total Assets
$7.615B
total Debt
$0.597B
net Income
$395.474M
eps
$2.04
gross Margin
68.7%
cash Position
$1.250B
revenue Growth
+11.4%

Revenue Breakdown

SegmentRevenueGrowth
Net product revenues$2,308,438,000+3.7%
Royalty and other revenues$38,250,000+16.6%

Key Numbers

Key Players & Entities

FAQ

What caused BioMarin Pharmaceutical Inc.'s net loss in Q3 2025?

BioMarin Pharmaceutical Inc. reported a net loss of $30.744 million for the three months ended September 30, 2025, primarily due to a significant increase in research and development (R&D) expenses, which rose by 121.4% to $409.478 million from $184.901 million in Q3 2024.

How did BioMarin's revenue perform in the third quarter of 2025?

BioMarin's net product revenues increased by 3.7% to $760.812 million for the three months ended September 30, 2025, up from $733.867 million in the same period of 2024. Total revenues for the quarter were $776.133 million.

What was BioMarin's net income for the first nine months of 2025?

For the nine months ended September 30, 2025, BioMarin Pharmaceutical Inc. reported a net income of $395.474 million, an increase from $301.916 million in the corresponding period of 2024.

What are the key risks highlighted for BioMarin Pharmaceutical Inc. in this filing?

Key risks for BioMarin include managing growth, successfully developing new products, competing effectively in product sales, obtaining and maintaining adequate coverage and reimbursement for products, and navigating extensive ongoing regulatory requirements from the FDA, EC, and EMA.

How much cash and cash equivalents did BioMarin have as of September 30, 2025?

As of September 30, 2025, BioMarin Pharmaceutical Inc. had cash and cash equivalents totaling $1,250,108 thousand, an increase from $942,842 thousand at December 31, 2024.

What was the impact of acquisitions on BioMarin's cash flow in the first nine months of 2025?

During the nine months ended September 30, 2025, BioMarin's investing activities included an acquisition, net of cash acquired, of $285.193 million, contributing to net cash used in investing activities of $371.793 million.

What is BioMarin's focus as a biotechnology company?

BioMarin Pharmaceutical Inc. is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company aims to unleash the full potential of genetic science by pursuing category-defining medicines.

How many shares of common stock were outstanding for BioMarin as of October 23, 2025?

As of October 23, 2025, BioMarin Pharmaceutical Inc. had 192,114,344 shares of common stock, par value $0.001, outstanding.

What was BioMarin's total operating expenses for the three months ended September 30, 2025?

BioMarin's total operating expenses for the three months ended September 30, 2025, were $822.825 million, a significant increase from $631.847 million in the same period of 2024.

What is the significance of BioMarin's high per-patient prices for its products?

Because the target patient populations for BioMarin's products are relatively small, the company must achieve significant market share and maintain high per-patient prices for its products to achieve and maintain profitability, as stated in the 'Risk Factors Summary'.

Risk Factors

Industry Context

The biotechnology and pharmaceutical industry is characterized by high R&D investment, lengthy development cycles, and stringent regulatory oversight. Companies like BioMarin focus on specialized therapeutic areas, often rare diseases, to differentiate themselves. The competitive landscape demands continuous innovation and strategic acquisitions to maintain a robust pipeline and market position.

Regulatory Implications

BioMarin operates under the strict scrutiny of global regulatory bodies such as the FDA, EC, and EMA. Compliance with their requirements is paramount for drug approval, manufacturing, and marketing. Any misstep or delay in regulatory processes can significantly impact revenue and profitability.

What Investors Should Do

  1. Monitor R&D spending efficiency
  2. Assess acquisition integration success
  3. Evaluate long-term growth drivers

Key Dates

Glossary

Net product revenues
Revenue generated from the sale of the company's pharmaceutical products. (Primary revenue driver for BioMarin, showing a 3.7% increase in Q3 2025.)
Research and development (R&D) expenses
Costs incurred in the process of discovering, developing, and testing new drugs and therapies. (Significantly increased by 121.4% in Q3 2025, impacting the company's quarterly profitability but indicating investment in future growth.)
Acquired in-process research & development expense
The value attributed to research and development projects acquired as part of a business combination that have not yet reached technological feasibility. (A substantial expense of $220.963 million was recognized, reflecting strategic acquisitions.)
Goodwill
An intangible asset that arises when a company acquires another business for a price greater than the fair value of its identifiable net assets. (Represents the premium paid for acquisitions, valued at $196.199 million as of September 30, 2025.)
Weighted average common shares outstanding, diluted
The average number of a company's outstanding common shares over a period, adjusted to include the potential effect of dilutive securities like stock options and convertible debt. (Used to calculate diluted earnings per share, which was $ (0.16) for Q3 2025.)

Year-Over-Year Comparison

Compared to the prior year, BioMarin experienced a significant shift in quarterly profitability, moving from a net income of $106.080 million in Q3 2024 to a net loss of $30.744 million in Q3 2025, primarily due to a 121.4% surge in R&D expenses. Despite this, net product revenues saw a modest 3.7% increase. For the nine-month period, net income grew to $395.474 million from $301.916 million, and total revenues increased by 11.4%. New risks related to managing substantial acquisitions and their associated R&D costs have emerged.

Filing Stats: 4,463 words · 18 min read · ~15 pages · Grade level 16.9 · Accepted 2025-10-28 14:07:10

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q contains "forward-looking statements" as defined under securities laws. Many of these statements can be identified by the use of terminology such as "believes," "expects," "intends," "anticipates," "plans," "may," "will," "could," "would," "projects," "continues," "estimates," "potential," "opportunity" or the negative versions of these terms and other similar expressions. Our actual results or experience could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in "Risk Factors," in Part II, Item 1A of this Quarterly Report on Form 10-Q as well as information provided elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (the SEC) on February 24, 2025. You should carefully consider that information before you make an investment decision. You should not place undue reliance on these types of forward-looking statements, which speak only as of the date that they were made. These forward-looking statements are based on the beliefs and assumptions of the Company's management based on information currently available to management and should be considered in connection with any written or oral forward-looking statements that the Company may issue in the future as well as other cautionary statements the Company has made and may make. Except as required by law, the Company does not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Quarterly Report on Form 10-Q to reflect later events or circumstances or the occurrence of unanticipated events. The discussion of the Company's financial condition and results of operations should be read in conjunction with the Company's Condensed Consolidated Financial Statements and

Financial Statements 3

Financial Statements 3 Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 4 Condensed Consolidated Statement of Stockholders' Equity (Unaudited) for the three and nine months ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements (Unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations 21

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures about Market Risk 32

Quantitative and Qualitative Disclosures about Market Risk 32 Item 4.

Controls and Procedures 32

Controls and Procedures 32 PART II. OTHER INFORMATION 33 Item 1. Legal Proceedings 33 Item 1A. Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 63 Item 3. Defaults Upon Senior Securities 63 Item 4. Mine Safety Disclosures 63 Item 5. Other Information 63 Item 6. Exhibits 65 SIGNATURES 66 2

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements BIOMARIN PHARMACEUTICAL INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Three and Nine Months Ended September 30, 2025 and 2024 (In thousands, except per share amounts) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 REVENUES: Net product revenues $ 760,812 $ 733,867 $ 2,308,438 $ 2,073,811 Royalty and other revenues 15,321 11,873 38,250 32,791 Total revenues 776,133 745,740 2,346,688 2,106,602 OPERATING EXPENSES: Cost of sales 140,085 188,457 441,733 444,096 Research and development 409,478 184,901 729,517 573,675 Selling, general and administrative 268,415 253,480 706,810 742,418 Intangible asset amortization 4,847 5,009 14,540 33,606 Gain on sale of nonfinancial assets — — — ( 10,000 ) Total operating expenses 822,825 631,847 1,892,600 1,783,795 INCOME (LOSS) FROM OPERATIONS ( 46,692 ) 113,893 454,088 322,807 Interest income 17,854 18,053 55,694 57,203 Interest expense ( 2,579 ) ( 2,968 ) ( 8,121 ) ( 10,089 ) Other income, net 5,093 5,463 7,972 2,203 INCOME (LOSS) BEFORE INCOME TAXES ( 26,324 ) 134,441 509,633 372,124 Provision for income taxes 4,420 28,361 114,159 70,208 NET INCOME (LOSS) $ ( 30,744 ) $ 106,080 $ 395,474 $ 301,916 EARNINGS (LOSS) PER SHARE, BASIC $ ( 0.16 ) $ 0.56 $ 2.06 $ 1.59 EARNINGS (LOSS) PER SHARE, DILUTED $ ( 0.16 ) $ 0.55 $ 2.04 $ 1.56 Weighted average common shares outstanding, basic 192,032 190,429 191,639 189,806 Weighted average common shares outstanding, diluted 192,032 197,147 196,893 196,683 COMPREHENSIVE INCOME (LOSS) $ ( 20,116 ) $ 83,931 $ 299,884 $ 335,354 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 3 BIOMARIN PHARMACEUTICAL INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2025 and December 31, 2024 (In thousands, except share amounts) September 30, 2025 December 31, 2024 ASSETS (unaudited) Current assets: Cash and cas

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing